


# I PRD SPARK



## Inside This Edition

Tesla Challenges Avanci's SEP Pool Pricing in UK Supreme Court

---

FDA Approves First Gene Therapy for Genetic Hearing Loss

---

Google Cloud Unveils Eighth-Gen TPUs for Scalable AI Infrastructure

---

Global Regulators Advance Smarter Oversight for AI-Enabled Medical Devices

Curated insights shaping the future of  
Intellectual Property and R&D.

# Welcome to IPRD Spark | May Edition

---

**The future does not arrive all at once. It shows up in signals.**


A new patent pilot here. A gene therapy milestone there. A shift in regulatory thinking. A breakthrough in AI-assisted chemistry. A court decision that redraws the boundaries of protection. Individually, these developments may seem like separate stories. Together, they offer a glimpse into where innovation is heading.

This edition of **IPRD Spark** follows those signals across industries, from patent strategy and legal developments to clean technologies, life sciences, AI infrastructure, consumer health, mobility, and standard essential patents.

What makes this month especially interesting is the range of movement: ideas are being tested, challenged, commercialized, regulated, and scaled simultaneously. The pace is no longer defined only by discovery, but by how quickly ecosystems respond to it.

**Through this issue, we invite you to look beyond the headlines and trace the patterns shaping the next wave of IP, R&D, and technology-led growth.**

**- Editorial team**






# CONTENTS

- 01** Industry News
- 02** Legal Watch
- 03** Techno Spotlight
- 04** Standard Essential Patents



# Industry News

Key Industry Developments and Updates



# USPTO Introduces Pier Pilot for Select PCT National Stage Applications

By: Ankur Saxena

**Apr' 26:** The United States Patent and Trademark Office (USPTO) has launched the PCT Informed Examination Request (PIER) Pilot Program **to study how applicants manage U.S. national stage applications after completion of the international phase.** Effective from April 9, 2026, through April 9, 2027, the pilot applies to selected unexamined national stage applications that have cleared pre-examination processing.

Under the program, the USPTO will issue a Requirement for Information (RFI), giving applicants the option to proceed with examination, defer examination for up to 12 months, or abandon the application.

A response must be filed within the prescribed period to avoid abandonment. The Office has also clarified that deferred examination may reduce Patent Term Adjustment (PTA).

The pilot is expected to influence global filing and portfolio management strategies, particularly for applicants handling large PCT portfolios and timing-sensitive innovations. ([Source](#)).



## EPO Fee Increases to Raise Cost Pressures for Global Patent Filers

By: Christy Titus George

**Apr' 26:** The European Patent Office (EPO) has revised its official fee schedule effective April 1, 2026, increasing key patent prosecution costs by around 5%. The European search fee has risen from **€1,520 to €1,595, while the examination fee for certain applications increased from €2,135 to €2,240.**

The changes are expected to influence budgeting and filing strategies for companies managing large international patent portfolios, particularly in technology, life sciences, and clean energy sectors. ([Source](#)).

## EPO and IEA Report Sharp Rise in Battery Recycling Patent Activity

By: Jitendra Shreemukh

**Apr' 26:** The European Patent Office and the International Energy Agency (IEA) have reported a **sharp rise in battery recycling and reuse innovation**, with patent filings in battery circularity technologies increasing more than sevenfold over the past decade.

The report highlights growing activity in battery collection, recycling, metal recovery, and repurposing technologies, driven by **rising EV demand** and concerns around critical mineral supply chains. The findings position battery circularity as a major emerging focus area for global R&D and patent activity. ([Source](#)).




# EPO Expands Electronic PCT Notifications through WIPO EPCT

By: Anuj Raj

**Apr' 26:** The European Patent Office (EPO) has announced that, **from June 1, 2026, applicants will be able to receive Patent Cooperation Treaty (PCT) communications electronically through WIPO's ePCT platform.** The update forms part of the EPO's broader push toward a fully digital patent-granting process and will replace paper-based notifications with electronic delivery for eligible PCT communications issued by the EPO.

To use the service, applicants must actively select ePCT as the notification method for each application individually. Once enabled, communications will be delivered electronically, with no corresponding paper copies issued. **Users already connected through MyEPO services may receive notifications through both systems.**

The development is expected to accelerate digital adoption across patent practices, requiring firms and corporate IP teams to further modernize docketing, workflow management, and prosecution processes in increasingly paperless filing environments. ([Source](#)).



# Legal Watch

Key Legal Developments in the IP Landscape



## Patents, Trade Secrets, and the Limits of Injunctions

By: Divya Arora

**Apr' 26:** Recent rulings emphasize that **California trade secret law cannot be stretched into a patent noncompete. In Cornell, the Federal Circuit held that information disclosed in patents or generally known cannot be recast as trade secrets.** A California injunction case similarly rejected attempts to bar a former inventor from ordinary patent-related work, underscoring that trade secret protection applies only to genuine confidential information.

The FLIR precedent reinforces that patent disputes or validity challenges are not misappropriation. **Courts also caution against equating mere possession of files with misuse** and note that most invalidity theories rely on public information rather than secret know-how.

These rulings draw a firm line: protect secrecy, but do not restrain public knowledge, professional skill, or lawful patent practice. ([Source](#))



## CAFC Distinguishes ‘Results-Oriented’ Claims from Claims with ‘Specificity and Structure’ in Eligibility Analysis

By: Divya Arora

**Apr’ 26:** The Federal Circuit in *Constellation Designs v. LG Electronics* clarified the line between abstract ideas and patent-eligible technology. **The court ruled that Constellation’s “optimization claims” were too broad and result-oriented to qualify under §101, while upholding the “constellation claims” as patent-eligible due to their specific technical implementation.**

The CAFC also affirmed findings of infringement and upheld the \$1.68 million damages award, rejecting LG’s challenges to the evidence and licensing analysis. ([Source](#))

## Monolithic Power Systems Wins Texas Patent Infringement Case Against Bel Power

By: Rahul Bhattacharya

**Apr’ 26:** Monolithic Power Systems (MPS) prevailed in a patent infringement lawsuit brought by Bel Power Solutions in the U.S. District Court for the Western District of Texas. **The court granted summary judgment of non-infringement on all asserted patents.**

The summary notes that **MPS also successfully challenged Bel Power’s patents at the USPTO through ex parte reexamination**, resulting in the cancellation of four patents. Following these rulings, Bel Power agreed to dismiss the case and pay \$50,000 in costs, illustrating the effectiveness of combining district court defense with USPTO post-grant proceedings. ([Source](#))



# CureVac Sues Moderna Over mRNA COVID 19 Vaccine Patent Infringement

By: Rahul Bhattacharya

**Apr' 26:** German biotech company CureVac, now owned by BioNTech, filed a patent infringement lawsuit against Moderna in the U.S. District Court for the District of Delaware. **The suit alleges that Moderna's Spikevax COVID-19 vaccine infringes eight CureVac patents covering key mRNA stabilization and delivery technologies.**

The litigation forms part of an expanding wave of high-stakes vaccine patent battles, with billions of dollars in royalties potentially at stake. **CureVac claims Moderna copied its proprietary mRNA engineering techniques**, while Moderna has said it will vigorously defend itself.

The case further intensifies the long-running patent wars surrounding COVID-19 vaccine innovations and could reshape licensing norms in the biotech industry. ([Source](#))



# Techno Spotlight

Breakthroughs Shaping the Future of  
Technology



## Scientists Teach AI To Think Like a Professional Chemist

By: Rachna Gupta

**Apr' 26:** Designing molecules is one of the most difficult tasks in chemistry. Whether creating new medicines or advanced materials, each compound must be built through a carefully planned sequence of reactions.

Mapping out these steps requires both deep technical knowledge and strategic thinking, which is why chemists often spend years developing this expertise. **A research team led by Philippe Schwaller at EPFL has developed a framework that interprets chemical strategy as language, opening a new path for AI-assisted discovery.** ([Source](#))

## New Water Filter Removes Hard-to-catch “Forever Chemicals”

By: Rachna Gupta

**Apr' 26:** PFAS, often called “**forever chemicals,**” have quietly spread through groundwater, rivers, and even treated drinking water, exposing millions of people worldwide. **Led by Dr. Witold Bloch, the team developed a nano-sized molecular cage designed to act as a highly selective ‘PFAS trap’.**

This nano-engineered “cage” may succeed where traditional filters struggle, capturing the smallest and most mobile PFAS molecules and opening a new path for cleaner water. ([Source](#))



## Could This New Weight-Loss Pill Disrupt the Entire Market?

By: Rachna Gupta

**Apr' 26:** A new daily pill is emerging as a potential contender in the evolving landscape of weight-loss and diabetes treatments. **Orforglipron is a new oral GLP-1 drug that outperforms oral semaglutide in blood sugar control and weight loss** while offering easier manufacturing and storage, though it may cause more side effects.

The drug, orforglipron, is showing stronger results than current oral options for both lowering blood sugar and reducing body weight, raising the possibility of a simpler alternative to injections. ([Source](#))

## Forget Chemicals, this Plant Removes Microplastics from Water

By: Rachna Gupta

**Apr' 26:** Researchers in Brazil have identified a surprising ally in the fight against microplastic pollution: **Moringa oleifera**.

Moringa seed extract **can remove microplastics from water by causing the particles to agglomerate for easier filtration**. It performs as well as, and sometimes better than, traditional chemical treatments.

The saline extract from the seeds performs similarly to aluminum sulfate, which is used in treatment plants to coagulate microplastic-contaminated water. ([Source](#))

## Key M&A/Strategic Alliances

**Apr' 26:**

- Shell announces agreement to acquire Canadian energy company, ARC Resources Ltd ("ARC") ([Source](#))
- UPM and Mark Andy renew strategic partnership in the Americas ([Source](#))
- The Board of Directors of UPM-Kymmene Corporation has approved a demerger plan concerning the separation of the Plywood business into a new listed company. ([Source](#))
- bp has agreed to acquire a 60% interest in three offshore exploration blocks in Namibia from Eco Atlantic Oil & Gas as part of bp's strategy to grow its upstream portfolio. ([Source](#))



## Intellia's CRISPR Therapy Marks Phase 3 Breakthrough in Hereditary Angioedema

By: Manash Pratim Barkataki

**Apr' 26:** Intellia Therapeutics reported landmark Phase 3 results from its global HAELO trial, positioning lonvoguran ziclumeran (lonvo z) as a potential first-in-class, one-time therapy for hereditary angioedema (HAE).

The in vivo CRISPR gene-editing treatment met its primary and all key secondary endpoints, reducing HAE attacks **by 87% versus placebo over six months. Notably, 62% of treated patients were entirely attack-free and no longer required ongoing prophylactic therapy.**

Lonvo z demonstrated favorable safety, with only mild-to-moderate treatment-emergent adverse events. Intellia has initiated a rolling U.S. FDA biologics license application, targeting a potential U.S. launch in the first half of 2027 if approved. ([Source](#))

## Historic FDA Approval: First Gene Therapy Cleared for OTOF Related Hearing Loss

By: Manash Pratim Barkataki

**Apr' 26:** The U.S. FDA has approved Otarmeni (lunsotogene parvec cwha), the first ever gene therapy for genetic hearing loss, marking a major milestone in precision medicine. This dual AAV-based, one-time gene therapy treats **severe to profound sensorineural hearing loss caused by biallelic OTOF gene mutations.**

Approved just 61 days after BLA submission under the FDA's National Priority Voucher Program, Otarmeni is the first gene therapy cleared through this accelerated pathway.

Clinical results showed hearing improvement in 80% of evaluable pediatric patients, addressing a condition for which no prior disease-modifying treatments were available. The approval underscores rapid regulatory progress for high-impact rare disease therapies. ([Source](#))



## FDA Grants Second Breakthrough Status to Avim Therapy for Uncontrolled Hypertension

By: Aparajita Basu

**Apr' 26:** Orchestra BioMed has received a second U.S. FDA Breakthrough Device Designation for its Atrioventricular Interval Modulation (AVIM) Therapy, strengthening its path toward broader clinical use.

**AVIM Therapy is a pacemaker-based treatment designed to lower blood pressure in patients whose hypertension remains uncontrolled despite medication.** The new designation expands coverage beyond pacemaker recipients to include a wider population at high cardiovascular risk, **an estimated 7.7 million adults in the U.S.**

The breakthrough status is expected to accelerate development, support favorable reimbursement pathways, and improve timely patient access, while Orchestra BioMed continues its pivotal BACKBEAT clinical trial in collaboration with Medtronic. ([Source](#))

## Real Time AI Imaging Aims to Reduce Re operations in Breast Cancer Surgery

By: Aparajita Basu

**Apr' 26:** Perimeter Medical Imaging AI unveiled Claire™ OCT+AI at the 2026 American Society of Breast Surgeons (ASBrS) meeting, marking its first public showcase ahead of commercial launch.

Having recently received FDA Premarket Approval, **Claire is the first AI-enabled imaging system approved in the U.S. for intraoperative breast cancer margin assessment.**

The system combines wide field optical coherence tomography (OCT) with proprietary AI to deliver real-time, high-resolution imaging of excised tissue—up to ten times the resolution of standard X-ray or ultrasound.

Designed to help surgeons identify residual cancer during breast-conserving surgery, Claire has the potential to reduce reoperations and improve surgical precision. ([Source](#))



## Intel Launches Core Series 3 Processors With AI-Ready Architecture

By: Chandandeep Kaur

**Apr' 26:** Intel has launched its **Intel Core™ Series 3 processors, built on the advanced 18A process node and designed for AI-ready mainstream computing.** Featuring hybrid architecture with up to 40 platform TOPS, the processors support AI workloads across commercial PCs, education, and edge devices.

The platform delivers notable performance gains over previous generations and supports next-generation connectivity technologies, including Wi-Fi 7, Bluetooth 6, and Thunderbolt™ 4—strengthening scalable AI-enabled computing across consumer and enterprise environments. ([Source](#))


## TSMC Unveils Next Generation A13 Process Technology

By: Chandandeep Kaur

**Apr' 26:** TSMC has introduced its **A13 process technology, delivering improved power efficiency, performance, and ~6% area reduction through advanced nanosheet transistor design.**

Compatible with the existing A14 platform, the node is aimed at AI, high-performance computing, and advanced mobile applications.

With production planned for 2029, the announcement reinforces TSMC's long-term focus on advanced semiconductor scaling and AI-driven demand. ([Source](#))



## Google Cloud Introduces Eighth-Gen TPUS for Scalable AI Infrastructure

By: Chandandeep Kaur

**Apr' 26:** Google Cloud has introduced its **8th-generation TPUs (TPU 8t and TPU 8i) for large-scale AI training and inference.**

The chips deliver up to **3× faster training and ~80% better performance-per-dollar** than previous generations, supporting hyperscale AI deployments with clusters of over one million interconnected TPUs.

The launch reflects Google's continued push toward scalable, energy-efficient AI infrastructure through a combination of custom silicon and heterogeneous computing. ([Source](#))


## Qualcomm Plots Entry in Data Center Market, Working with Hyperscaler

By: Chandandeep Kaur

**Apr' 26:** Qualcomm is expanding into the data center market with custom silicon solutions for hyperscale cloud providers, targeting large-scale AI and inference workloads.

Developed in collaboration with a leading hyperscaler, **the platform focuses on optimized compute, memory, and energy-efficient performance for scalable AI infrastructure.**

Initial shipments are expected in Q4 2026, reflecting Qualcomm's long-term push into next-generation data center computing. ([Source](#))



## Suntory Expands into Self-Care with Daiichi Sankyo Healthcare Acquisition

By: Simmi Kapoor

**Apr' 26:** Suntory Holdings has announced the **acquisition of Daiichi Sankyo Healthcare** as part of its strategy to expand beyond food and beverages into the growing self-care and wellness market.

The deal strengthens Suntory's presence in health-focused consumer products by adding established OTC, skincare, and oral care brands.

By combining Daiichi Sankyo Healthcare's capabilities with its own strengths in branding and innovation, Suntory aims to build a broader consumer-centric health and wellness business. ([Source](#))

## PepsiCo and Partners Sign Renewable Energy Deal to Support European Decarbonization

By: Simmi Kapoor

**Apr' 26:** PepsiCo, Givaudan, Smurfit WestRock, and Statkraft **have signed a 10-year renewable energy agreement tied to a wind asset in Spain**, supporting efforts to decarbonize operations and supply chains across Europe.

Part of PepsiCo's **pep+ REnew program**, the collaboration pools energy demand to secure long-term renewable electricity at scale.

The agreement is expected to reduce nearly 32,000 metric tons of CO<sub>2</sub> emissions annually while supporting broader grid decarbonization efforts. ([Source](#))



## DolCas Biotech Introduces Single-Serve Collagen Sachets for Beauty Nutrition

By: Akshyansh Kumar

**Apr' 26:** DolCas Biotech has launched a **single-serve sachet format for its Morikol marine collagen tripeptides**, targeting convenience in the growing ingestible beauty market.

The flavorless powder dissolves instantly without water, addressing common usability challenges associated with collagen supplements.

The launch reflects rising consumer demand for portable, easy-to-use beauty nutrition products with enhanced absorption and convenience. ([Source](#))

## TopGum Expands Women's Health Portfolio with Functional Gummies

By: Akshyansh Kumar

**Apr' 26:** TopGum has launched a new women's **health gummy range featuring botanical and nutrient blends targeting hormonal health, PMS, menopause support, and nausea relief.**

The products combine ingredients such as shatavari, Vitex, magnesium, ginger, and vitamin B6 in no-added-sugar formulations.

The launch reflects growing consumer demand for convenient, functional supplements tailored to women's health and wellness needs. ([Source](#))



## Global Regulators Advance Smarter Oversight for Medical Devices

By: Basharat Ahmed Sofi

**Apr' 26:** The MDCG and IMDRF have introduced new measures to **strengthen oversight of conventional, IVD, and AI-enabled medical devices.**

Updates include revised EU guidance on device classification and regulatory pathways, as well as a draft global framework for AI lifecycle management.

The initiatives emphasize risk management, cybersecurity, transparency, human oversight, and real-world performance, reflecting growing regulatory focus on safe and trustworthy medical device innovation. ([Source 1](#); [Source 2](#); [Source 3](#)).

## EU Tightens Cosmetic Safety Rules While US Maintains Different Standards

By: Mayank Kakkar

**Apr' 26:** The **EU has banned 15 chemicals from cosmetic products after classifying them as carcinogenic, mutagenic, or toxic for reproduction,** requiring affected products to be removed from shelves starting May 1.

The same substances remain permitted in U.S. cosmetics, reflecting differing regulatory approaches between the regions.

While the EU follows hazard-based classification, U.S. regulations focus more on demonstrated exposure risks, highlighting ongoing debate around global cosmetic safety standards. ([Source](#))



## FDA Moves to Withdraw Approval for Tavneos

By: Jiju Narayanan

**Apr' 26:** The FDA's Centre for Drug Evaluation and Research (CDER) has proposed **withdrawing approval of Tavneos (avacopan), citing concerns over the drug's demonstrated effectiveness and undisclosed issues** related to the pivotal clinical study.

The agency also raised safety concerns, including serious cases of drug-induced liver injury. While Tavneos will remain available during the ongoing regulatory process, the development highlights increasing scrutiny around clinical data integrity and post-approval safety oversight. ([Source](#)).

## FDA Advances Safety Framework for Genome Editing Therapies

By: Basharat Ahmad Sofi

**Apr' 26:** The FDA has issued draft guidance on the use of next-generation sequencing (NGS) to assess safety risks in gene therapy and genome-edited products. **The framework outlines approaches for detecting off-target edits, unintended genomic changes,** and impacts on genomic integrity during nonclinical studies.

The guidance reflects a growing regulatory focus on precision safety assessment as genome-editing technologies continue to advance toward broader clinical adoption. ([Source](#))



## FDA Explores AI-Enabled Real-Time Clinical Trial Oversight

By: Mukul Singh

**Apr' 26:** The FDA has announced new initiatives to modernize clinical trial oversight through real-time regulatory review and AI-enabled trial optimization. **In collaboration with AstraZeneca and Amgen, the agency is testing cloud-based systems that allow regulators to monitor safety signals and trial endpoints as they emerge.**

The move reflects a broader shift toward continuous data review, with the goal of improving trial efficiency, accelerating decision-making, and potentially shortening drug development timelines. ([Source](#)).


## Cannabis Use May Affect Cognitive Development in Teenagers

By: Megha Walia

**Apr' 26:** Teenagers who start using cannabis may show slower gains in memory, attention, language, and processing speed, according to a UC San Diego study of more than 11,000 youth in the ABCD Study.

Researchers **found cognitive growth tended to level off after cannabis initiation, with THC exposure linked to poorer memory trajectories.**

Although causality was not proven, the findings highlight adolescence as a vulnerable period for brain development and support delaying cannabis use to protect learning and everyday cognitive function. ([Source](#)).



# FDA Reopens Pathway for Testosterone Therapy Expansion

By: Basharat Ahmad Sofi

**Apr' 26:** The US FDA is encouraging testosterone replacement therapy manufacturers to seek expanded **indications for men with low libido linked to idiopathic hypogonadism.**

Citing emerging **evidence of quality-of-life benefits, the agency invited sponsors to discuss data requirements**, emphasizing that any approval must demonstrate substantial effectiveness and a favorable benefit-risk profile.

The move follows expert discussions suggesting TRT may be appropriate for selected men with unexplained low testosterone, despite longstanding concerns and regulatory limits around safety, misuse, and controlled-substance status. ([Source](#)).



## Toyota Maintains Multi-Powertrain Strategy Amid Uneven EV Adoption

By: Nitesh Kumar

**Apr' 26:** Toyota has reaffirmed its commitment to combustion engine development, **citing uneven EV adoption, infrastructure gaps, and regional market differences.**

The company plans to offer multiple powertrain options in future models, including ICE, hybrid, plug-in hybrid, and EV variants.

**Toyota is also investing in more efficient gasoline engines and exploring carbon-neutral fuels** with partners such as Mazda and Subaru to extend the relevance of combustion technologies. ([Source](#))

## Polestar Slams Plug-in Hybrids

By: Nitesh Kumar

**Apr' 26:** Polestar Australia's boss calls plug-in **hybrids "the worst of both worlds,"** citing added complexity, weight, maintenance, and the fact that many owners rarely charge them, making them inefficient.

He says PHEVs are becoming irrelevant as EV tech improves. **Critics note that EVs still aren't universal solutions,** that infrastructure is uneven, and that modern PHEVs with long electric range still fill an important transitional role. ([Source](#))



## Porsche is Walking Away from Bugatti Rimac

By: Sachin Patel

**Apr' 26:** Porsche is exiting Bugatti Rimac and Rimac Group, **selling its 45% Bugatti Rimac and 20.6% Rimac Group stakes to a New York consortium led by HOF Capital, an investor in SpaceX and Anthropic.**

Terms are undisclosed and subject to regulatory approval. The move aligns with Porsche's strategy to refocus on its core business amid a costly EV transition and broader market pressures. ([Source](#))

## The Smart Car Is Finally Tiny Again

By: Sachin Patel

**Apr' 26:** Smart's new #2 concept revives the **tiny ForTwo formula as a China-built, Mercedes-designed, city-focused EV.**

Riding on the Electric Compact Architecture, it targets about 186 miles (300 km) of range, over double the old EQ ForTwo, and **10–80% fast charging in under 20 minutes, plus V2L capability.** Debuting in production form at the Paris Motor Show, it will be one of Europe's smallest EVs. ([Source](#))



# Standard Essential Patents

Standard Essential Patent (SEP) Landscape



## Tesla Challenges Avanci's SEP Pool Pricing in UK Supreme Court

By: Jitendra Shreemukh

**Apr' 26:** The UK Supreme Court has heard **Tesla's appeal against InterDigital and the Avanci patent pool in a closely watched SEP dispute over royalty pricing for 5G-connected vehicles.**

The case raises broader questions around whether courts can determine FRAND rates for patent pools.

With major industry players intervening, the outcome could significantly influence global SEP licensing practices and the balance between licensors and implementers in pool-based models. ([Source](#)).

## Panasonic Secures SEP Injunction Against HMD in Brazil

By: Jitendra Shreemukh

**Apr' 26:** Panasonic has obtained a preliminary injunction against HMD Global in Brazil over alleged infringement of AAC standard-essential patents.

**The court ruled that Panasonic satisfied its FRAND obligations by offering licensing through the Via Licensing Alliance AAC patent pool.**

The decision strengthens the legal standing of patent pool-based licensing and highlights Brazil's growing role as an active venue for SEP enforcement. ([Source](#)).



## Disney Faces Expanding HEVC SEP Litigation Across Europe

By: Jitendra Shreemukh

**Apr' 26:** Velos Media has joined Sharp and Huawei in pursuing HEVC-related **SEP litigation against Disney, escalating an ongoing dispute over video compression technologies used in streaming platforms.**

The actions span the Munich Regional Court and the UPC ecosystem following unsuccessful licensing negotiations.

The case highlights growing pressure around codec-related SEP enforcement and the increasing use of multi-jurisdictional litigation in global licensing disputes. ([Source](#)).

## InterDigital Nears \$500M Smartphone Licensing Milestone

By: Jitendra Shreemukh

**Apr' 26:** InterDigital reported strong momentum in its **smartphone licensing business, nearing \$500 million in annual recurring revenue following a major renewal agreement with Xiaomi and several new licensing deals.**

Beyond smartphones, the company also expanded agreements across consumer electronics and IoT segments, highlighting the growing importance of long-term licensing partnerships in driving stable SEP revenue growth. ([Source](#)).



# Editorial Team | IPRD Spark



Christy T George  
Founding Editor



Mukesh Kumar  
Co-Editor



Sumedha Sardana  
Editor, Design & Content



Akshyansh Kumar  
Section Editor  
(Consumer Goods)



Aparajita Basu  
Section Editor  
(Life Sciences)



Basharat Ahmad Sofi  
Section Editor  
(Chemical Safety & Regulatory Affairs)



Chandandeep Kaur  
Section Editor  
(Hi-Tech)



Jitendra Prakash Shreemukh  
Section Editor  
(Standard Essential Patents)



Rachna Gupta  
Section Editor  
(Chemicals & Materials)



Atul Kumar Pal  
Section Researcher  
(Hi-tech)



Hansprabha Mudgal  
Section Researcher  
(Chemical Safety & Regulatory Affairs)



Nitesh Kumar  
Section Editor  
(Automobile, e-mobility & Mechanical)



Rahul Bhattacharya  
Section Researcher  
(Legal Watch & Industry News)



Sachin Patel  
Section Researcher  
(Automobile, e-mobility & Mechanical)



Simmi Kapoor  
Section Researcher  
(Consumer Goods)



Divya Arora  
Section Editor  
(Legal Watch & Industry News)

# From Our Archives

A look back at recent editions, capturing key moments and developments across the evolving world of intellectual property and innovation.

[April 2026](#)

[March 2026](#)

[February 2026](#)

[January 2026](#)

[December 2025](#)



# Stay Connected with IP and R&D

---

Evalueserve IP and R&D supports organizations across the innovation lifecycle, from early-stage research to commercialization.

Our teams provide specialized services in patent research, technology scouting, competitive intelligence, and IP analytics, helping clients navigate complex technology landscapes and make informed innovation decisions.

Contribute insights or suggestions at:  
[iprdsparknewsletter@evalueserve.com](mailto:iprdsparknewsletter@evalueserve.com)

By combining deep domain expertise with analytical capabilities, we enable organizations to identify opportunities, strengthen IP portfolios, and stay ahead in an increasingly innovation-driven environment.

